drugset
Drugs / Serplulimab
last change 10 days ago re-read 8 days ago

Serplulimab

also known as HLX10 · Serplulimab+SOX · Serplulimab, mFOLFOX6 · Srulimab

Monoclonal antibody targets PDCD1 via inhibition

Developed for
small cell lung carcinoma · non-small cell lung carcinoma · colorectal cancer · rectal cancer · cervical cancer · esophageal squamous cell carcinoma · gastric cancer · gastroesophageal junction adenocarcinoma
+48 more · hepatocellular carcinoma · gastric adenocarcinoma · metastasis from malignant tumor of colon · colorectal carcinoma · pancreatic ductal adenocarcinoma · rectal carcinoma · triple-negative breast carcinoma · acoustic neuroma · biliary tract cancer · cancer · meningioma · neoplasm · NF2-related schwannomatosis · non-small cell squamous lung carcinoma · peritoneal neoplasm · rectum adenocarcinoma · adenocarcinoma · breast cancer · carcinoma · carcinoma of esophagus · chronic hepatitis B virus infection · colon adenocarcinoma · colon carcinoma · colorectal adenocarcinoma · diffuse large B-cell lymphoma · digestive system carcinoma · esophageal small cell neuroendocrine carcinoma · exocrine pancreatic carcinoma · female breast carcinoma · gastric neoplasm · gastroesophageal adenocarcinoma · gastroesophageal cancer · head and neck carcinoma · head and neck squamous cell carcinoma · high grade malignant neoplasm · hormone receptor-positive breast cancer · lung adenocarcinoma · lung carcinoma · malignant pancreatic neoplasm · metastatic malignant neoplasm in the brain · nasopharyngeal carcinoma · neuroendocrine carcinoma · neuroendocrine neoplasm · nonpapillary renal cell carcinoma · pancreatic exocrine neoplasm · progesterone-receptor negative breast cancer · renal cell adenocarcinoma · urothelial carcinoma
Investigated by
Shanghai Henlius Biotech · Fudan University · Sun Yat-sen University · Tianjin Medical University Cancer Institute and Hospital · West China Hospital · Fujian Cancer Hospital
+64 more · Henan Cancer Hospital · RenJi Hospital · Second Affiliated Hospital, School of Medicine, Zhejiang University · Shanghai Zhongshan Hospital · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Zhejiang Cancer Hospital · Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Guangdong Provincial People's Hospital · Tang-Du Hospital · Xijing Hospital · Beijing Tiantan Hospital · Henlix, Inc · Peking Union Medical College Hospital · Shanghai Changzheng Hospital · Sichuan Cancer Hospital and Research Institute · Xinhua Hospital, Shanghai Jiao Tong University School of Medicine · Zhejiang University · AccuTarget MediPharma (Shanghai) Co., Ltd · Changhai Hospital · Changxing People's Hospital · Chongqing University Cancer Hospital · Daping Hospital and the Research Institute of Surgery of the Third Military Medical University · First Affiliated Hospital of Wenzhou Medical University · First Affiliated Hospital of Zhejiang University · Fujian Medical University Union Hospital · Guangdong Association of Clinical Trials · Guangzhou FineImmune Biotechnology Co., LTD. · Guangzhou No.12 People's Hospital · Hebei Medical University Fourth Hospital · Hunan Cancer Hospital · Jiangsu Cancer Institute & Hospital · Liaoning Cancer Hospital & Institute · National Cancer Center, Japan · Ningbo Medical Center Lihuili Hospital · Ningbo No. 1 Hospital · Ningbo No.2 Hospital · Peking University Shenzhen Hospital · People's Hospital of Quzhou · Qilu Hospital of Shandong University · Ruijin Hospital · Second Affiliated Hospital of Soochow University · Second Affiliated Hospital of Wenzhou Medical University · Second Xiangya Hospital of Central South University · Shanghai Chest Hospital · Sichuan University · Sir Run Run Shaw Hospital · Sun Yat-sen University Cancer Center · Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University · Tao Zhang · The 986th Military Hospital · The Affiliated People's Hospital of Ningbo University · The Central Hospital of Lishui City · The First Affiliated Hospital of Zhengzhou University · The First Affiliated Hospital with Nanjing Medical University · Tongji Hospital · Wuhan TongJi Hospital · Xi Junjie · Xiujuan Qu · Yang Jianjun, PhD · Ye Xu · Yu jiren · Zekuan Xu · Zhangzhou Municipal Hospital of Fujian Province

Regulatory milestones approvals, filings & regulatory actions · 6 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Filed esophageal squamous cell carcinoma 1 milestone
Filed China (NMPA) HANSIZHUANG esophageal squamous cell carcinoma 2022-12-02

“the new drug application (NDA) of serplulimab for the treatment of ESCC has been accepted by the National Medical Products Administration (NMPA).” henlius.com ↗

“The NDA of Serplulimab for the treatment of ESCC has been accepted by the National Medical Products Administration (NMPA).” henlius.com ↗
Filed gastroesophageal adenocarcinoma 1 milestone
Filed China (NMPA) HANSIZHUANG gastroesophageal adenocarcinoma 2025-12-12

“has been accepted by the National Medical Products Administration (NMPA) and granted Priority Review.” henlius.com ↗
Filed non-small cell squamous lung carcinoma 1 milestone
Filed China (NMPA) — non-small cell squamous lung carcinoma 2021-09-17

“the NDA of serplulimab for first-line treatment of locally advanced or metastatic sqNSCLC has been accepted by the NMPA” henlius.com ↗
Filed small cell lung carcinoma 2 milestones
Filed EU (EMA) HANSIZHUANG small cell lung carcinoma 2023-03-23

“the European Medicines Agency (EMA) has validated the application for its self-developed anti-PD-1 monoclonal antibody (mAb) HANSIZHUANG (serplulimab)” henlius.com ↗

“Its Marketing Authorisation Application (MAA) for ES-SCLC has been validated by the European Medicines Agency (EMA)” henlius.com ↗

“In March 2023, EMA validated the marketing authorisation application (MAA) of HANSIZHUANG for ES-SCLC.” henlius.com ↗

“Its marketing application has been validated by the European Medicines Agency (EMA) in March 2023” henlius.com ↗

“1 marketing applications is under review in EU” henlius.com ↗
Filed US (FDA) HANSIZHUANG small cell lung carcinoma —

“Based on the positive feedback from the US Food and Drug Administration (FDA) Biologics License Application (BLA) submission for HANSIZHUANG for the treatment of ES-SCLC” henlius.com ↗
Approved Indication not stated 1 milestone
Approved EU (EMA) Hetronifly — 2025-02-03 europa.eu ↗

Trials 148 · started per year

today
EU approved 2025
2
8
3
2
16
36
25
25
31
20182019202020212022202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 17 trials
Phase 1 NCT07231445 Apr 2026 → Dec 2028 expected small cell lung carcinoma Suzhou Zelgen Biopharmaceuticals Co.,Ltd Recruiting No outcome recorded
Phase 1 NCT06302062 Jun 2023 → Dec 2025 overdue neoplasm Guangzhou FineImmune Biotechnology Co., LTD. Recruiting No outcome recorded
Phase 1 NCT05442996 Jan 2023 → Apr 2024 cancer Shanghai Henlius Biotech Unknown No outcome recorded
Phase 1 NCT05483530 Dec 2022 → Dec 2024 — Shanghai Henlius Biotech Unknown No outcome recorded
Phase 1 NCT05400265 Jul 2022 → Aug 2023 — Shanghai Henlius Biotech Completed No outcome recorded
Phase 1 NCT03757936 Nov 2018 → Sep 2019 neoplasm Shanghai Henlius Biotech Unknown No outcome recorded
Phase 1 NCT03468751 Feb 2018 → Jun 2020 cancer Henlix, Inc Unknown No outcome recorded
Phase 1/210 trials
Phase 1/2 NCT07708285 Jul 2026 → Dec 2028 expected NF2-related schwannomatosis, acoustic neuroma, meningioma Beijing Tiantan Hospital Not yet recruiting No outcome recorded
Phase 1/2 NCT07358585 Jan 2026 → Jul 2027 expected colon adenocarcinoma Shanghai Henlius Biotech Not yet recruiting No outcome recorded
Phase 1/2 NCT07141771 Dec 2025 → Jun 2030 expected small cell lung carcinoma Cancer Institute and Hospital, Chinese Academy of Medical Sciences Not yet recruiting No outcome recorded
Phase 1/2 NCT07182565 Nov 2025 → Aug 2029 expected gastroesophageal junction adenocarcinoma West China Hospital Recruiting No outcome recorded
Phase 1/2 NCT07175389 Oct 2025 → Sep 2027 expected pancreatic ductal adenocarcinoma West China Hospital Not yet recruiting No outcome recorded
Phase 1/2 NCT06848699 Feb 2025 → Oct 2026 expected non-small cell lung carcinoma Shanghai Henlius Biotech Recruiting No outcome recorded
Phase 1/2 NCT05747729 Jun 2023 → Oct 2026 expected neuroendocrine carcinoma Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Recruiting No outcome recorded
Phase 1/2 NCT05882630 Jun 2023 → Jun 2025 small cell lung carcinoma Fujian Cancer Hospital Unknown No outcome recorded
Phase 1/2 NCT05641493 Feb 2023 → Mar 2025 non-small cell lung carcinoma Shanghai Henlius Biotech Unknown No outcome recorded
Phase 1/2 NCT05501340 Sep → Dec 2022 peritoneal neoplasm Second Affiliated Hospital of Soochow University Unknown No outcome recorded
Phase 299 trials
Phase 2 NCT07779694 Oct 2026 → Dec 2028 expected rectal carcinoma Zhejiang University Not yet recruiting No outcome recorded
Phase 2 NCT07819604 Sep 2026 → Sep 2027 expected colorectal cancer Xijing Hospital Not yet recruiting No outcome recorded
Phase 2 NCT07713745 Jul 2026 → Jun 2036 expected NF2-related schwannomatosis, acoustic neuroma, ependymoma, meningioma Beijing Tiantan Hospital Not yet recruiting No outcome recorded
Phase 2 NCT07699939 Jul 2026 → Nov 2028 expected gastric adenocarcinoma, gastroesophageal junction adenocarcinoma National Cancer Center, Japan Not yet recruiting No outcome recorded
Phase 2 NCT07621484 Jul 2026 → May 2028 expected gastric adenocarcinoma, gastroesophageal junction adenocarcinoma Shanghai Changzheng Hospital Not yet recruiting No outcome recorded
Phase 2 NCT07691632 Jun 2026 → Dec 2027 expected colorectal adenocarcinoma Tianjin Medical University Cancer Institute and Hospital Not yet recruiting No outcome recorded
Phase 2 NCT07622550 Jun 2026 → Dec 2027 expected colorectal cancer Jiangsu Cancer Institute & Hospital Not yet recruiting No outcome recorded
Phase 2 NCT07527520 Jun 2026 → Jul 2028 expected rectal cancer Fudan University Not yet recruiting No outcome recorded
Phase 2 NCT07596121 May 2026 overdue non-small cell lung carcinoma Tang-Du Hospital Recruiting No outcome recorded
Phase 2 NCT07604909 May 2026 → Sep 2027 expected colorectal cancer Fudan University Recruiting No outcome recorded
Phase 2/35 trials · 1 missed
Phase 2/3 NCT07318883 Mar 2026 → Jan 2031 expected non-small cell squamous lung carcinoma Shanghai Henlius Biotech Not yet recruiting No outcome recorded
Phase 2/3 NCT07134218 Oct 2025 → Oct 2027 expected rectal cancer Changhai Hospital Not yet recruiting No outcome recorded
Phase 2/3 NCT06280495 Feb 2024 → Dec 2026 expected metastasis from malignant tumor of colon Sun Yat-sen University Recruiting No outcome recorded
Phase 2/3 NCT05807893 May 2023 → Mar 2024 metastatic malignant neoplasm in the brain, non-small cell lung carcinoma Sun Yat-sen University Completed No outcome recorded
Phase 2/3 NCT04547166 Mar 2021 → Sep 2025 overdue colorectal cancer Shanghai Henlius Biotech Recruiting Missed primary
Phase 318 trials · 5 met primary
Phase 3 NCT07113275 May 2026 → Jan 2028 expected rectal carcinoma Tao Zhang Recruiting No outcome recorded
Phase 3 NCT07551479 May 2026 → Dec 2032 expected rectal cancer Fudan University Not yet recruiting No outcome recorded
Phase 3 NCT07336953 Feb 2026 → Jul 2027 expected pancreatic ductal adenocarcinoma West China Hospital Not yet recruiting No outcome recorded
Phase 3 NCT07277842 Dec 2025 → Dec 2028 expected rectum adenocarcinoma Sun Yat-sen University Not yet recruiting No outcome recorded
Phase 3 NCT07235930 Nov 2025 → Jul 2029 expected exocrine pancreatic carcinoma Zhejiang Cancer Hospital Recruiting No outcome recorded
Phase 3 NCT07177443 Sep 2025 → Dec 2035 expected nasopharyngeal carcinoma Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Recruiting No outcome recorded
Phase 3 NCT07020247 Nov 2024 → Jul 2027 expected rectal cancer West China Hospital Recruiting No outcome recorded
Phase 3 NCT05173272 Jul 2023 → Dec 2027 expected cervical cancer Sichuan Cancer Hospital and Research Institute Recruiting No outcome recorded
Phase 3 NCT05468489 Nov 2022 → Feb 2026 overdue small cell lung carcinoma Shanghai Henlius Biotech Active not recruiting No outcome recorded
Phase 3 NCT04465734 Nov 2022 → Oct 2023 hepatocellular carcinoma Shanghai Henlius Biotech Withdrawn No outcome recorded
Phase 42 trials
Phase 4 NCT07446465 Mar 2026 → Jan 2027 expected colorectal cancer Ye Xu Not yet recruiting No outcome recorded
Phase 4 NCT06388135 May 2024 → May 2026 overdue esophageal squamous cell carcinoma Yang Jianjun, PhD Not yet recruiting No outcome recorded
Phase not applicable7 trials
— NCT07854964 Oct 2026 → May 2030 expected — Tang-Du Hospital Not yet recruiting No outcome recorded
— NCT07674342 Jun 2026 → Jun 2028 expected adenocarcinoma Tongji Hospital Not yet recruiting No outcome recorded
— NCT06688786 Nov 2024 → Jul 2025 overdue rectal cancer Xinhua Hospital, Shanghai Jiao Tong University School of Medicine Active not recruiting No outcome recorded
— NCT06580665 Sep 2024 → Sep 2028 expected non-small cell lung carcinoma Shanghai Chest Hospital Not yet recruiting No outcome recorded
— NCT06335147 Apr 2024 → Jan 2026 metastasis from malignant tumor of colon Henan Cancer Hospital Unknown No outcome recorded
— NCT06364046 Apr → Dec 2024 small cell lung carcinoma The Central Hospital of Lishui City Unknown No outcome recorded
— NCT06156332 Jan 2024 → Jan 2025 overdue neuroendocrine neoplasm Shanghai Changzheng Hospital Not yet recruiting No outcome recorded
Comparator or background therapy18 trials
Phase 1 NCT06716619 Background Feb 2025 → Dec 2026 expected neoplasm Guangzhou FineImmune Biotechnology Co., LTD. Recruiting No outcome recorded
Phase 1 NCT06394414 Background Apr 2024 → Apr 2027 expected neoplasm MediLink Therapeutics (Suzhou) Co., Ltd. Active not recruiting No outcome recorded
Phase 1 NCT06115642 Background Nov 2023 → Jun 2026 overdue metastatic malignant neoplasm Shanghai Henlius Biotech Enrolling by invitation No outcome recorded
Phase 2 NCT07854977 Background Nov 2026 → May 2029 expected pancreatic ductal adenocarcinoma Tianjin Medical University Cancer Institute and Hospital Not yet recruiting No outcome recorded
Phase 2 NCT07391826 Background Feb → Dec 2026 expected gastric carcinoma The First Affiliated Hospital with Nanjing Medical University Not yet recruiting No outcome recorded

News releases announcing trial results or a regulatory action · 105

DateIssuerRelease
2026-08-20 Shanghai Henlius Biotech Results Comprehensive First-Line Coverage Across Advanced Lung Cancer, Henlius’ Serplulimab to Feature in Seven Studies at WCLC 2026 henlius.com ↗
Serplulimab combined with chemotherapy demonstrated encouraging clinical activity and acceptable safety as a first-line treatment for LCNEC in this ongoing trial, supporting further exploration in this rare and aggressive malignancy.
2026-07-06 Shanghai Henlius Biotech Results Henlius’ Serplulimab Final Analysis in nsqNSCLC Published in Cancer Communications, Reinforcing Durable Survival Benefit henlius.com ↗
The study showed that serplulimab plus chemotherapy achieved a median overall survival (mOS) of 26.8 months.
2026-07-03 Shanghai Henlius Biotech Regulatory Lotus Pharmaceutical and Henlius Announce MFDS Approval of SERPLUMA® (serplulimab) for First-Line Treatment of ES-SCLC henlius.com ↗
The MFDS approval was supported by results from the global phase 3 ASTRUM-005 study, a randomized, double-blind trial involving 585 treatment-naïve patients with ES-SCLC.
2026-07-02 Shanghai Henlius Biotech Regulatory HETRONIFLY® (SERPLULIMAB) FORMALLY ENTERS ROUTINE USE IN THE NHS FOLLOWING NICE RECOMMENDATION, BECOMING THE FIRST ANTI-PD-1 IMMUNOTHERAPY FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCER IN ENGLAND and WALES henlius.com ↗
Accord Healthcare UK (Accord) and Shanghai Henlius Biotech, Inc. (2696.HK) recently announced that HETRONIFLY® (serplulimab) has been recommended by the National Institute for Health and Care Excellence (NICE) for routine use within the National Health Service (NHS) in England and Wales.
2026-06-26 Shanghai Henlius Biotech Regulatory Henlius’ Serplulimab Receives European Approval for a Fourth Indication, Expanding Its First-Line Treatment Footprint in Major High-Burden Cancers henlius.com ↗
The European Commission (EC) has approved a new indication for serplulimab (trade name: Hetronifly® in Europe) for squamous non-small cell lung cancer (sqNSCLC)
2026-06-23 Shanghai Henlius Biotech Results Henlius’ Serplulimab Marks Third Publication in a Leading International Journal, with Small Cell Lung Cancer Long-Term Survival Data Published in JAMA Oncology and a 4-Year OS Rate of 21.9% henlius.com ↗
The final analysis confirmed that serplulimab delivers durable and clinically meaningful survival benefits for patients with ES-SCLC, accompanied by a contemporaneous editor’s note that highly recognized the durable clinical benefit this study brings to patients with ES-SCLC.
2026-06-17 Shanghai Henlius Biotech Regulatory Exploring Earlier-Stage Treatment Potential: Henlius’ Phase 2 Clinical Trial of HLX43 in Combination with Serplulimab for Neoadjuvant Treatment of NSCLC Approved for Clinical Trial in Australia henlius.com ↗
2026-06-09 Shanghai Henlius Biotech Regulatory Henlius’ Serplulimab Approved for Perioperative Gastric Cancer, Pioneering a Chemotherapy-Sparring Adjuvant Approach henlius.com ↗
With this approval, serplulimab becomes the first and only* anti-PD-1 mAb in the world approved for perioperative treatment of gastric cancer, filling a long-standing clinical gap in this setting.
2026-06-02 Shanghai Henlius Biotech Results Featured in Both The Lancet and ASCO: Henlius’ Serplulimab Pioneers a New Perioperative Chemotherapy-Sparring Regimen for Gastric Cancer henlius.com ↗
Median EFS by BICR was also significantly prolonged in the serplulimab group (NR vs. 52.0 months; HR=0.67), translating into a 33% reduction in recurrence risk.
2026-05-23 Shanghai Henlius Biotech Regulatory Henlius' Serplulimab Receives Positive CHMP Opinion for the Treatment of sqNSCLC henlius.com ↗
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of a new indication for serplulimab (trade name: Hetronifly® in Europe) for squamous non-small cell lung cancer (sqNSCLC)
2026-05-22 Shanghai Henlius Biotech Results ASCO 2026: Henlius’ Serplulimab Unveils 8 Major Studies, Highlighted by the Global Debut of Perioperative Gastric Cancer Data with Significant Improvement in EFS and pCR Rate of 21.6% henlius.com ↗
pCR was achieved in 30.0% (9/30), and MPR in 56.7% (17/30).
2026-05-19 Shanghai Henlius Biotech Results ESTRO 2026 | Henlius' Serplulimab Achieves 42.5% pCR Rate in Neoadjuvant Colon Cancer; Study Results Presented Orally henlius.com ↗
The results showed that radiochemotherapy combined with serplulimab demonstrated favorable efficacy, with the pathological complete response (pCR) rate significantly increased to 42.5%, representing more than a four-fold improvement over the control group.

All press releases naming this drug 152 releases

DateIssuerRelease
Show all 152 releases opens the full record — a long page

Evidence & citations 9 cited values

Every value below carries the sentence it was read from. 168 sources stand behind the page.

FieldValueCited text
Known as Serplulimab “YL201 (High dose, medium dose and low dose; Q3W) in Combination with Serplulimab (4.5mg/kg; Q3W) with or without Platinum(70 mg/m2; Q3W)-based Chemotherapy.” NCT06394414 ↗
127

“Serplulimab will be administered concurrently with chemotherapy at a fixed dose of 300 mg via intravenous infusion on Day 1 of each 3-week cycle.” NCT07182565 ↗

“OBJECTIVE: We report the efficacy and safety of serplulimab, a novel humanized anti-programmed death-1 antibody, plus nanoparticle albumin-bound” PMID 37153587 ↗ Apr 2023

“iTNT group receives short-course radiotherapy (25Gy/5Fx) followed by 6 cycles of Serplulimab combined with CAPOX.” NCT07551479 ↗

“PD-1 inhibitor includes pembrolizumab，Nivolumab，Sintilimab，tislelizumab，Triplimab，Camrelizumab, Serplulimab.” NCT06702566 ↗

“Nivolumab or Pembrolizumab or Tislelizumab or Serplulimab or Toripalimab or Sintilimab or Camrelizumab” NCT06084897 ↗

“Preoperative treatment with 4-6 cycles of mFOLFOX6 regimen combined with serplulimab” NCT06688786 ↗

“Serplulimab (HLX10, Recombinant Anti-PD-1 Humanized Monoclonal Antibody)” NCT05513573 ↗

“Serplulimab 300 mg IV infusion on day 1 every 21 days.” NCT06599827 ↗

“Serplulimab 3mg/kg day IV for every three weeks” NCT07854977 ↗

“combined with serplulimab (200mg ivgtt Q3W)” NCT07101679 ↗

Show 117 more sources
Known as HLX10 “Perioperative HLX10 (Serplulimab) With S-1+Oxaliplatin (SOX) in Locally Advanced and PD-L1-Positive Gastric or Esophagogastric Junction Adenocarcinoma” NCT07699939 ↗
41

“HLX10 is an innovative monoclonal antibody targeting PD-1，developed by Shanghai Henlius Biotech, Inc.” NCT04150575 ↗

“HAIC+Serplulimab（HLX10）+ Bevacizumab Biosimilar（HLX04）” NCT06370065 ↗

“Treatment of CHB patient with HLX10” NCT04133259 ↗

NCT03952403 ↗

NCT05483530 ↗

NCT05246982 ↗

NCT03757936 ↗

NCT03468751 ↗

NCT03958890 ↗

NCT04301739 ↗

Show 31 more sources
Known as Serplulimab+SOX ClinicalTrials.gov intervention name — accepted as the source's own label NCT06496789 ↗
Known as Serplulimab, mFOLFOX6 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06335147 ↗
Known as Srulimab “patients can eventually be enrolled and receive PD-1 monoclonal antibody (Serplulimab, Srulimab) combined with mFOLFOX6 (oxaliplatin, fluorouracil) regimen, 2 weeks for 1 cycle.” NCT06335147 ↗
Action Inhibit “Functional programmed death 1 blockade was observed across dose levels.” PMID 38194016 ↗ Jan 2024
Modality Monoclonal antibody “HLX10 is a new monoclonal antibody targeting PD1 on T cells” NCT03468751 ↗
Route Intravenous “HLX10, at three dose levels (1, 3, 10 mg/kg), to be intravenously injected once every two weeks” NCT03757936 ↗
Target PDCD1 “HLX10 is a new monoclonal antibody targeting PD1 on T cells” NCT03468751 ↗